Comparing nasal high flow therapy with different cannulas for COPD patients
Nasal High Flow (NHF) in COPD - Effects on Ventilation With Asymmetrical Nasal Cannulas (NHFDuet)
This study is testing how well two different types of nasal cannulas work with high flow therapy to help people with worsening COPD breathe better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Kliniken Essen-Mitte Academic / other |
| Locations | 1 site (Essen, NRW) |
| Trial ID | NCT05676502 on ClinicalTrials.gov |
What this trial studies
This controlled randomized crossover study aims to evaluate the physiological effects of nasal high flow therapy (NHF) using two different nasal cannulas in patients experiencing exacerbated chronic obstructive pulmonary disease (ECOPD). A total of 20 patients will undergo NHF therapy during wakefulness, with physiological measurements taken across three visits: one without NHF, one with a standard cannula, and one with an asymmetrical cannula, all in randomized order. The study will assess various respiratory parameters to determine the effectiveness of each cannula type in improving respiratory function.
Who should consider this trial
Good fit: Ideal candidates include inpatients with COPD classified as GOLD stages 2, 3, or 4 who are in a stable phase following an acute exacerbation.
Not a fit: Patients with acute respiratory insufficiency, severe acute physical diseases, or those who cannot provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the management of COPD exacerbations by identifying the most effective nasal cannula for NHF therapy.
How similar studies have performed: Previous studies have shown varying effects of different nasal cannulas in NHF therapy, indicating that this approach has potential but may also yield novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Inpatients with COPD GOLD 3 and 4 in stable phase after acute exacerbation * Inpatients with COPD GOLD (2, 3 and 4) * Informed Consent Exclusion Criteria: * Acute respiratory insuffiency with respiratory acidosis (pH\<7.35) * Severe acute physical disease, that do not allow the subject to participate in a clinical trial * Language, cognitive, or other barriers that make study participation impossible * Pregnancy or Nursing
Where this trial is running
Essen, NRW
- Georg N Nilius — Essen, Nrw, Germany (Recruiting)
Study contacts
- Study coordinator: Georg N Nilius, Prof. Dr. med
- Email: G.Nilius@kem-med.com
- Phone: +49 201 174
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.